2.60Open2.60Pre Close0 Volume23 Open Interest3.00Strike Price0.00Turnover1198.64%IV2.91%PremiumJan 17, 2025Expiry Date2.59Intrinsic Value100Multiplier6DDays to Expiry0.01Extrinsic Value100Contract SizeAmericanOptions Type-0.7028Delta0.5515Gamma0.16Leverage Ratio-0.0179Theta-0.0003Rho-0.11Eff Leverage0.0002Vega
Relmada Therapeutics Stock Discussion
Dow Jones· 5 mins ago
Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
Relmada Therapeutics has Commenced a Process to Explore Strategic Alternatives to Maximize Shareholder Value
Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial Is Futile at Its Interim Analysis and Is Unlikely to Meet the Primary Efficacy Endpoint With Statistical Significance
No comment yet